Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07632690CT.gov QLC5508 in Participants With Metastatic Prostate Cancer | — | Not Yet Recruiting | — | — | — |
NCT07333066CT.gov Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial. | — | Recruiting | — | — | — |
NCT07516704CT.gov Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study | — | Not Yet Recruiting | — | — | — |
NCT07344779CT.gov A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice | — | Active Not Recruiting | — | — | — |
NCT07358806CT.gov Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06931340CT.gov Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | — | Recruiting | — | — | — |
NCT07172685CT.gov Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC | — | Recruiting | — | — | — |
NCT06925737CT.gov A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | — | Recruiting | — | — | — |
NCT06769425CT.gov HS-10502 Combination Treatment in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06652607CT.gov PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer | — | Recruiting | — | — | — |
Show 147 more trialsShow fewer
NCT06446401CT.gov The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer | — | Recruiting | — | — | — |
NCT06568094CT.gov A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT05627752CT.gov Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage | — | Unknown | — | — | — |
NCT06430411CT.gov Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | — | Not Yet Recruiting | — | — | — |
NCT06387056CT.gov Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) | — | Recruiting | — | — | — |
NCT06282588CT.gov Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers | — | Recruiting | — | — | — |
NCT05848011CT.gov A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT05733351CT.gov Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | — | Terminated | — | — | — |
NCT05818683CT.gov A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT05348577CT.gov Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) | — | Active Not Recruiting | — | — | — |
NCT05189457CT.gov First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04812366CT.gov Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer | — | Recruiting | — | — | — |
NCT04663997CT.gov 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT07428642CT.gov PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC. | — | Completed | — | — | — |
NCT04220398CT.gov Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer | — | Unknown | — | — | — |
NCT03700099CT.gov Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide | — | Unknown | — | — | — |
NCT03517969CT.gov M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03837353CT.gov A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 | — | Terminated | — | — | — |
NCT03879122CT.gov A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer | — | Unknown | — | — | — |
NCT03582475CT.gov Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | — | Active Not Recruiting | — | — | — |
NCT03218826CT.gov PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT03678025CT.gov Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT03574571CT.gov A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03311555CT.gov A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) | — | Completed | — | — | — |
NCT03343977CT.gov Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | — | Withdrawn | — | — | — |
NCT03358563CT.gov Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer | — | Completed | — | — | — |
NCT03338790CT.gov An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer | — | Completed | — | — | — |
NCT03246347CT.gov A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03093272CT.gov A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT03043989CT.gov Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin | — | Terminated | — | — | — |
NCT06473259CT.gov Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients | — | Recruiting | — | — | — |
NCT02793765CT.gov Docetaxel Followed by Provenge in Metastatic Prostate Cancer | — | Withdrawn | — | — | — |
NCT02793219CT.gov Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer | — | Withdrawn | — | — | — |
NCT02799602CT.gov Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer | — | Completed | — | — | — |
NCT02565901CT.gov Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT02685267CT.gov Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT02649855CT.gov Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer | — | Completed | — | — | — |
NCT02494921CT.gov LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC | — | Completed | — | — | — |
NCT02494713CT.gov Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer | — | Terminated | — | — | — |
NCT02366494CT.gov Micro RNAs to Predict Response to Androgen Deprivation Therapy | — | Completed | — | — | — |
NCT03258320CT.gov A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients | — | Recruiting | — | — | — |
NCT02182622CT.gov LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel | — | Withdrawn | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01619813CT.gov Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01603420CT.gov External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer | — | Terminated | — | — | — |
NCT02105675CT.gov Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01468532CT.gov Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01400555CT.gov A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | — | Completed | — | — | — |
NCT01385228CT.gov Pazopanib, Docetaxel, Prednisone Prostate | — | Completed | — | — | — |
NCT01087580CT.gov Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer | — | Withdrawn | — | — | — |
NCT01254513CT.gov Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients | — | Completed | — | — | — |
NCT01188187CT.gov Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer | — | Completed | — | — | — |
NCT01145508CT.gov Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT01084655CT.gov Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01188408CT.gov Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer | — | Withdrawn | — | — | — |
NCT01155791CT.gov Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer | — | Terminated | — | — | — |
NCT00574769CT.gov Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer | — | Completed | — | — | — |
NCT00879619CT.gov Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients | — | Terminated | — | — | — |
NCT00916123CT.gov Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer | — | Completed | — | — | — |
NCT00786682CT.gov Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer | — | Terminated | — | — | — |
NCT00808418CT.gov A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00937417CT.gov S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors | — | Withdrawn | — | — | — |
NCT00651326CT.gov Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer | — | Terminated | — | — | — |
NCT00728663CT.gov Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00528866CT.gov Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | — | Completed | — | — | — |
NCT00642018CT.gov A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer | — | Completed | — | — | — |
NCT00577356CT.gov Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer | — | Terminated | — | — | — |
NCT00663832CT.gov A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer | — | Completed | — | — | — |
NCT00617669CT.gov A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer | — | Completed | — | — | — |
NCT00527124CT.gov Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | — | Terminated | — | — | — |
NCT00589420CT.gov Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy | — | Completed | — | — | — |
NCT00466440CT.gov A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients | — | Completed | — | — | — |
NCT00539968CT.gov A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | — | Terminated | — | — | — |
NCT00503984CT.gov A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients | — | Terminated | — | — | — |
NCT00514267CT.gov An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors | — | Completed | — | — | — |
NCT00488982CT.gov Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC) | — | Completed | — | — | — |
NCT00565227CT.gov Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. | — | Terminated | — | — | — |
NCT00465725CT.gov A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT00619996CT.gov Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00405210CT.gov Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer | — | Completed | — | — | — |
NCT00134056CT.gov S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy | — | Completed | — | — | — |
NCT00327340CT.gov Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC | — | Completed | — | — | — |
NCT00321698CT.gov Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer | — | Terminated | — | — | — |
NCT00314782CT.gov Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC | — | Completed | — | — | — |
NCT00288444CT.gov Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer | — | Terminated | — | — | — |
NCT00273338CT.gov DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]) | — | Terminated | — | — | — |
NCT00498797CT.gov E3-Hormone Refractory Prostrate Cancer Taxotere Combination | — | Completed | — | — | — |
NCT00459186CT.gov The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer | — | Completed | — | — | — |
NCT00327288CT.gov Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients | — | Completed | — | — | — |
NCT00258388CT.gov Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | — | Completed | — | — | — |
NCT01172028CT.gov Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00268593CT.gov Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer | — | Completed | — | — | — |
NCT00251225CT.gov A Study of Imatinib and Docetaxel in Prostate Cancer | — | Completed | — | — | — |
NCT00268476CT.gov Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | — | Active Not Recruiting | — | — | — |
NCT00133224CT.gov Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients | — | Terminated | — | — | — |
NCT01076335CT.gov Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer | — | Completed | — | — | — |
NCT00861471CT.gov Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer | — | Terminated | — | — | — |
NCT00183937CT.gov Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer | — | Terminated | — | — | — |
NCT00293371CT.gov Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer | — | Terminated | — | — | — |
NCT00087165CT.gov GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00260611CT.gov Study of Oxaliplatin and Taxotere in Prostate Cancer | — | Completed | — | — | — |
NCT00104715CT.gov Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00482807CT.gov Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer | — | Completed | — | — | — |
NCT00193271CT.gov Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer | — | Completed | — | — | — |
NCT00089856CT.gov GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer | — | Terminated | — | — | — |
NCT00085228CT.gov Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate | — | Completed | — | — | — |
NCT00165399CT.gov Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment | — | Completed | — | — | — |
NCT00083005CT.gov Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate | — | Completed | — | — | — |
NCT00456989CT.gov Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer | — | Completed | — | — | — |
NCT00126230CT.gov Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer | — | Terminated | — | — | — |
NCT00072930CT.gov MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer | — | Completed | — | — | — |
NCT00027859CT.gov Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00074022CT.gov GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors | — | Completed | — | — | — |
NCT00186420CT.gov Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation | — | Completed | — | — | — |
NCT00587431CT.gov Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00500110CT.gov Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00080678CT.gov Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases | — | Completed | — | — | — |
NCT00242918CT.gov Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer | — | Completed | — | — | — |
NCT00084825CT.gov Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008 | — | Completed | — | — | — |
NCT00471432CT.gov OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | — | Completed | — | — | — |
NCT00058253CT.gov Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors | — | Completed | — | — | — |
NCT00136526CT.gov Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer | — | Completed | — | — | — |
NCT00055731CT.gov Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse | — | Completed | — | — | — |
NCT00176527CT.gov Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | — | Terminated | — | — | — |
NCT00052845CT.gov Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | — | Completed | — | — | — |
NCT00050596CT.gov Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer | — | Completed | — | — | — |
NCT00030654CT.gov Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00283829CT.gov Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00043576CT.gov ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere | — | Unknown | — | — | — |
NCT00045227CT.gov Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00215345CT.gov A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer | — | Unknown | — | — | — |
NCT00582582CT.gov Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer | — | Terminated | — | — | — |
NCT00024167CT.gov Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer | — | Terminated | — | — | — |
NCT00038194CT.gov Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer | — | Completed | — | — | — |
NCT00046826CT.gov Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy | — | Completed | — | — | — |
NCT00016107CT.gov Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT01250717CT.gov Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer | — | Completed | — | — | — |
NCT00017563CT.gov Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer | — | Completed | — | — | — |
NCT00014352CT.gov Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00005810CT.gov Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy | — | Completed | — | — | — |
NCT00020046CT.gov Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00004001CT.gov S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy | — | Completed | — | — | — |
NCT00005627CT.gov Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | — | Completed | — | — | — |
NCT00003633CT.gov Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer | — | Unknown | — | — | — |
NCT00002775CT.gov Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | — | Unknown | — | — | — |
NCT00003103CT.gov Chemotherapy in Treating Patients With Solid Tumors | — | Completed | — | — | — |
NCT00811031CT.gov Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC) | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Docetaxel (this asset) | National Cancer Institute (NCI) | P3 | BB · 67 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Docetaxel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P4 | BBB · 73 |
| Pancreatic Adenocarcinoma | — | P2 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Docetaxel in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/docetaxel-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →